• Braveheart Bio will present at the American Heart Association Scientific Sessions in Chicago, Nov. 6-9, 2026.
• A Nov. 6 late-breaking presentation will cover 52-week extension results on BHB-1893's efficacy and safety in obstructive hypertrophic cardiomyopathy.
• A second presentation on Nov. 6 will address BHB-1893's effects on diastolic function in non-obstructive hypertrophic cardiomyopathy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Braveheart Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610300730PRIMZONEFULLFEED9856742) on October 30, 2026, and is solely responsible for the information contained therein.